MedDataX Logo

Non-Abstinence Outcomes in Methamphetamine Use Disorder

NCT ID: NCT07226596

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-05

Study Completion Date

2031-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methamphetamine Use Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

methamphetamine treatment behavioral intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

This group will receive payment for providing urine samples throughout the trial.

Group Type NO_INTERVENTION

No interventions assigned to this group

Contingency Management Group

This group will receive payment for providing methamphetamine negative urine samples throughout the trial.

Group Type EXPERIMENTAL

Contingency Management

Intervention Type BEHAVIORAL

Subjects will receive payments for providing methamphetamine negative urine samples.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Contingency Management

Subjects will receive payments for providing methamphetamine negative urine samples.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* be age 18 years or older;
* self-report methamphetamine use in the week prior to screening;
* provide a methamphetamine-positive urine sample at screening;
* meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);
* be seeking treatment for their methamphetamine use
* be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up
* Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion Criteria

* current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians
* poor venous access precluding blood draws
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

William Stoops

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

William Stoops

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William W Stoops, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Kentucky

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

William W Stoops, PhD

Role: CONTACT

Phone: 8592575388

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01DA064144

Identifier Type: NIH

Identifier Source: secondary_id

View Link

107171

Identifier Type: -

Identifier Source: org_study_id